Trevi Therapeutics (TRVI) Total Current Liabilities (2018 - 2026)

Trevi Therapeutics has reported Total Current Liabilities for 9 years, with the latest figure at $7.1 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 3.63% year-over-year to $7.1 million; the trailing twelve-month figure through Mar 2026 stood at $7.1 million (up 3.63% YoY), and the FY2025 full-year result was $9.7 million, down 7.23% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $7.1 million, down from $9.7 million in the prior quarter.
• The five-year high for Total Current Liabilities was $15.4 million in Q2 2022, with the low at $4.7 million in Q2 2023.
• Average Total Current Liabilities over 5 years is $9.3 million, with a median of $9.1 million recorded in 2024.
• Year-over-year, Total Current Liabilities soared 141.05% in 2022 and slumped 69.47% in 2023.
• Tracing TRVI's Total Current Liabilities over 5 years: stood at $13.4 million in 2022, then slumped by 56.54% to $5.8 million in 2023, then surged by 80.44% to $10.5 million in 2024, then decreased by 7.23% to $9.7 million in 2025, then dropped by 27.02% to $7.1 million in 2026.
• The last three Total Current Liabilities figures came in at $7.1 million (Q1 2026), $9.7 million (Q4 2025), and $9.0 million (Q3 2025), per Business Quant data.

Peer Comparison